drugset / Trial / NCT00160511

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

NCT00160511

Phase 2 Completed 170 enrolled UCB Pharma
RandomizedParallel-groupDouble-blind

Summary

16 week trial assessing the efficacy, safety, and tolerability of levetiracetam compared with placebo in the treatment of postherpetic neuralgia.

Timeline

Start
2004-04
Primary completion
2005-08
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg
Subject Levetiracetam Other / unclassified 3000 mg